Drug Approval | December 18, 2023
Zydus receives final approval from the USFDA for Lacosamide Tablets
Lacosamide is indicated to treat partial-onset seizures
Lacosamide is indicated to treat partial-onset seizures
The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The product will be manufactured at Lupin's Pithampur facility in India
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Receives registration of Valganciclovir powder for oral solution in Germany
Subscribe To Our Newsletter & Stay Updated
